BIOMAT Database Logo BIOMAT Database Logo

Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. 1977

R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010984 Platinum A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae". Platinum Black
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Polychemotherapy in advanced non-small-cell lung cancer.
September 1993, Lancet (London, England),
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Polychemotherapy in advanced non-small-cell lung cancer.
September 1993, Lancet (London, England),
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Polychemotherapy in advanced non-small-cell lung cancer.
September 1993, Lancet (London, England),
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Polychemotherapy in advanced non-small-cell lung cancer.
September 1993, Lancet (London, England),
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Lonidamine versus polychemotherapy in advanced non-small-cell lung cancer. A preliminary analysis.
February 1989, Tumori,
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?
September 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
ICRF-159 versus polychemotherapy in non-small cell lung cancer.
July 1976, Cancer treatment reports,
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis.
July 1993, Lancet (London, England),
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
May 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R T Eagan, and J N Ingle, and S Frytak, and J Rubin, and L K Kvols, and D T Carr, and D T Coles, and J R O'Fallon
Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
January 2009, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Copied contents to your clipboard!